NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00079352
- Locations
- 🇺🇸
University of New Mexico, Albuquerque, New Mexico, United States
CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Recurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00079235
- Locations
- 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States
FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma
Phase 2
Terminated
- Conditions
- Recurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Small Lymphocytic Lymphoma
- Interventions
- Biological: rituximabOther: laboratory biomarker analysis
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2013-07-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00079443
- Locations
- 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Docetaxel Plus Garlic in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Not Applicable
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00079170
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma
Phase 2
Completed
- Conditions
- Melanoma (Skin)
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00079144
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸NCI - Center for Cancer Research, Bethesda, Maryland, United States
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Phase 1
Completed
- Conditions
- Acute Undifferentiated LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaUnspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00079404
- Locations
- 🇺🇸
COG Phase I Consortium, Arcadia, California, United States
Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
Phase 3
Completed
- Conditions
- Adenocarcinoma of the ColonStage III Colon Cancer
- Interventions
- Drug: Locally Directed TherapyBiological: cetuximab
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3397
- Registration Number
- NCT00079274
- Locations
- 🇺🇸
Franklin Square Hospital Center, Baltimore, Maryland, United States
🇺🇸Hematology and Oncology Associates, Chicago, Illinois, United States
🇺🇸Case Western Reserve University, Cleveland, Ohio, United States
Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast Cancer
Phase 1
Completed
- Conditions
- Breast Neoplasms
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2018-07-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 22
- Registration Number
- NCT00079625
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 65
- Registration Number
- NCT00079040
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Biological: GTI-2040Other: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00078962
- Locations
- 🇺🇸
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath